

-1-

Date: <u>7.25.01</u> Express Mail Label No. <u>EL762235708US</u>
--

Inventors: David de Graaf and Eric S. Lander  
Attorney's Docket No.: 2825.2018-001

## DIFFERENTIAL GENE EXPRESSION IN INTESTINAL POLYPS

### RELATED APPLICATION

This application claims the benefit of U.S. Provisional Application No. 60/220,579, filed on July 25, 2000, the entire teachings of which are incorporated herein  
5 by reference.

### BACKGROUND OF THE INVENTION

Intestinal polyps are a common type of intestinal disorder, and are found in many diseases, including Gardner syndrome, Peutz-Jeghers syndromes, familial juvenile polyposis, and familial adenomatous polyposis coli. Most polyps do not cause  
10 symptoms and are found incidentally during a regular cancer screening exam or in the investigation of gastrointestinal complaints, yet identification and removal of these polyps are crucial to preventing intestinal cancer.

Classification of biological samples from individuals is not an exact science. In many instances, accurate diagnosis and safe and effective treatment of a disorder depend  
15 on being able to discern biological distinctions among cell or tissue samples from a particular area of the body, such as intestinal polyp samples and normal intestinal samples. The classification of a sample from an individual into particular disease classes has often proven to be difficult, incorrect, or equivocal. Typically, using traditional methods such as histochemical analyses, immunophenotyping, and  
20 cytogenetic analyses, only one or two characteristics of the sample are analyzed to determine the sample's classification. Inaccurate results can lead to incorrect diagnoses

00945479-072604

and potentially ineffective or harmful treatment. Thus, a need exists for an accurate and efficient method for identifying polyps and differentiating between polyps and normal tissue.

#### SUMMARY OF THE INVENTION

5           The present invention features methods of identifying an intestinal polyp, methods for identifying a compound that modulates intestinal polyp development, and oligonucleotide microarrays containing probes for genes involved in intestinal polyp formation.

10           In one aspect, the invention features a method of identifying an intestinal polyp, comprising obtaining a nucleic acid sample derived from intestinal tissue; and determining a gene expression profile from a gene expression product of at least one informative gene having increased expression in an intestinal polyp relative to a control. Increased expression of the informative gene in the sample is indicative of an intestinal polyp. In one embodiment, the intestinal polyp is an upper intestinal polyp or a colonic polyp. In another embodiment, the nucleic acid sample derived from intestinal tissue is 15 derived from upper intestinal tissue or colonic tissue. In other embodiments, the gene expression product is DNA or mRNA. Preferably, when the gene expression product is DNA or mRNA, the gene expression profile is determined utilizing specific hybridization probes. For example, the gene expression profile may be determined 20 utilizing oligonucleotide microarrays.

          In another embodiment of the first aspect of the invention, the gene expression product is a polypeptide. Preferably, when the gene expression product is a polypeptide, the gene expression profile is determined utilizing antibodies.

25           In still another embodiment, the one or more informative genes is selected from the group consisting of apoptosis genes, cell cycle genes, tumor suppressor genes, cell adhesion genes, transcription related genes, and inflammation genes. In a preferred embodiment, the one or more informative genes is selected from the group consisting of the genes in Figures 1A-1U.

The invention also features a method of identifying an intestinal polyp, comprising obtaining a polypeptide sample derived from intestinal tissue; and determining a gene expression profile from a gene expression product of at least one informative gene having increased expression in an intestinal polyp relative to a control, where the gene expression product is a polypeptide. Increased expression of the gene expression product in the sample is indicative of an intestinal polyp. In one embodiment, the intestinal polyp is an upper intestinal polyp or a colonic polyp. In another embodiment, the polypeptide sample derived from intestinal tissue is derived from upper intestinal tissue or colonic tissue. In another embodiment, the gene expression profile is determined utilizing antibodies. In yet another embodiment, the one or more informative genes is selected from the group consisting of apoptosis genes, cell cycle genes, tumor suppressor genes, cell adhesion genes, transcription related genes, and inflammation genes. In a preferred embodiment, the one or more informative genes is selected from the group consisting of the genes in Figures 1A-1U.

In addition, the invention features a method of identifying an intestinal polyp, comprising obtaining a nucleic acid sample derived from intestinal tissue; and determining a gene expression profile from a gene expression product of at least one informative gene having decreased expression in an intestinal polyp relative to a control. Decreased expression of the gene in the sample is indicative of an intestinal polyp. In one embodiment, the intestinal polyp is an upper intestinal polyp or a colonic polyp. In another embodiment, the nucleic acid sample derived from intestinal tissue is derived from upper intestinal tissue or colonic tissue. In other embodiments, the gene expression product is DNA or mRNA. Preferably, when the gene expression product is DNA or mRNA, the gene expression profile is determined utilizing specific hybridization probes. For example, the gene expression profile may be determined utilizing oligonucleotide microarrays.

In another embodiment, the gene expression product is a polypeptide. Preferably, when the gene expression product is a polypeptide, the gene expression profile is determined utilizing antibodies.

In still another embodiment, the one or more informative genes is selected from the group consisting of apoptosis genes, cell cycle genes, tumor suppressor genes, cell adhesion genes, transcription related genes, and inflammation genes. In yet another embodiment, the one or more informative genes is selected from the group consisting of the genes in Figures 1A-1U.

The invention also features a method of identifying an intestinal polyp, comprising obtaining a polypeptide sample derived from intestinal tissue; and determining a gene expression profile from a gene expression product of at least one informative gene having decreased expression in an intestinal polyp relative to a control, where the gene expression product is a polypeptide. Decreased expression of the gene expression product in the sample is indicative of an intestinal polyp. In one embodiment, the intestinal polyp is an upper intestinal polyp or a colonic polyp. In another embodiment, the polypeptide sample derived from intestinal tissue is derived from upper intestinal tissue or colonic tissue. In another embodiment, the gene expression profile is determined utilizing antibodies. In yet another embodiment, the one or more informative genes is selected from the group consisting of apoptosis genes, cell cycle genes, tumor suppressor genes, cell adhesion genes, transcription related genes, and inflammation genes. In still another embodiment, the one or more informative genes is selected from the group consisting of the genes in Figures 1A-1U.

The invention also features a method of identifying a compound for use in modulating intestinal polyp development, comprising the steps of: a) providing a cell or cell lysate sample; b) contacting the cell or cell lysate sample with a candidate compound; and c) detecting an increase in expression of at least one informative gene having decreased expression in an intestinal polyp. A candidate compound that increases the expression of the informative gene is a compound for use in modulating intestinal polyp development. In one embodiment, the intestinal polyp is an upper intestinal polyp or a colonic polyp. In another embodiment, the cell or cell lysate sample is derived from intestinal tissue. The intestinal tissue may be derived from upper intestinal tissue or colonic tissue. In another embodiment, the cell or cell lysate sample

is derived from a cultured cell. In other embodiments, gene expression is determined by assessing the DNA or mRNA level of the gene. Preferably, the DNA or mRNA level is determined utilizing specific hybridization probes. For example, the DNA or mRNA level may be determined utilizing oligonucleotide microarrays.

- 5           In another embodiment, gene expression is determined by assessing the polypeptide level encoded by the informative gene. Preferably, gene expression is determined utilizing antibodies.

          In another embodiment, the one or more informative genes is selected from the group consisting of apoptosis genes, cell cycle genes, tumor suppressor genes, cell  
10   adhesion genes, transcription related genes, and inflammation genes. In a preferred embodiment, the one or more informative genes is selected from the group consisting of the genes in Figures 1A-1U.

- In addition, the invention features a method of identifying a compound for use in modulating intestinal polyp development, comprising the steps of: a) providing a cell or  
15   cell lysate sample; b) contacting the cell or cell lysate sample with a candidate compound; and c) detecting a decrease in expression of at least one informative gene having increased expression in an intestinal polyp. A candidate compound that decreases the expression of the informative gene is a compound for use in modulating intestinal polyp development. In one embodiment, the intestinal polyp is an upper  
20   intestinal poly or a colonic polyp. In another embodiment, the cell or cell lysate sample is derived from intestinal tissue. The intestinal tissue may be derived from upper intestinal tissue or colonic tissue. In another embodiment, the cell or cell lysate sample is derived from a cultured cell. In other embodiments, gene expression is determined by assessing the DNA or mRNA level of the gene. Preferably, the DNA or mRNA level is  
25   determined utilizing specific hybridization probes. For example, the DNA or mRNA level may be determined utilizing oligonucleotide microarrays.

          In another embodiment, gene expression is determined by assessing the polypeptide level encoded by the informative gene. Preferably, gene expression is determined utilizing antibodies.

2825.2018-001

In another embodiment, the one or more informative genes is selected from the group consisting of apoptosis genes, cell cycle genes, tumor suppressor genes, cell adhesion genes, transcription related genes, and inflammation genes. In a preferred embodiment, the one or more informative genes is selected from the group consisting of the genes in Figures 1A-1U.

The invention also features a method for modulating intestinal polyp development in a subject by down-regulating in the subject at least one informative gene shown to be expressed in intestinal polyp tissue or expressed in increased levels, but not in normal intestinal tissue.

The invention also features a method for modulating intestinal polyp development in a subject by up-regulating in the subject at least one informative gene shown not to be expressed in intestinal polyp samples, or expressed in reduced levels relative to normal intestinal samples.

The invention also features an oligonucleotide microarray having immobilized thereon a plurality of oligonucleotide probes specific for one or more informative genes selected from the group consisting of the genes on Figures 1A-1U.

The invention also features an oligonucleotide microarray having immobilized thereon a plurality of oligonucleotide probes specific for one or more informative genes selected from the group consisting of apoptosis genes, cell cycle genes, tumor suppressor genes, cell adhesion genes, transcription related genes, and inflammation genes.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A-1V show the results of differential expression studies described herein. Figures 1A-1U are portions that complete a table listing the nucleic acid molecules which are differentially expressed in intestinal polyps and normal intestinal tissue. The first column of the table shows the nucleic acid molecule name, and the second column shows the Affymetrix annotation. Columns 3-6 show expression data for the colonic polyp samples (L1-L4; gray), and Columns 7-10 show expression data

for the normal colon samples (LC1-LC4). Columns 11-14 show expression data for the intestinal polyp samples (U1-U4; gray), and Columns 15-18 show expression data for the normal intestinal samples (UC1-UC4). Columns 19-20, 21-22, 23-24, and 25-26 show the average expression value and standard deviation, respectively, for the groups of colonic expression, small intestine expression, polyp expression, and normal tissue expression, respectively. Column 27 shows a short description of the function of the nucleic acid molecule shown in Column 1 (if available). Figure 1V provides a key depicting how Figures 1A-1U are assembled to produce a complete table.

#### DETAILED DESCRIPTION OF THE INVENTION

10           The present invention is directed to methods for predicting phenotypic classes of intestinal polyps, such as the presence or absence of an intestinal polyp, or the identification of compounds that modulate intestinal polyp development, based on gene expression profiles. In one aspect, the invention involves identifying an intestinal polyp by obtaining a nucleic acid or polypeptide sample derived from intestinal tissue, and  
15           determining a gene expression profile from a gene expression product of at least one informative gene having increased expression in an intestinal polyp relative to a control. Increased expression of the informative gene is indicative of the presence of an intestinal polyp in the sample. Alternatively, identification of a polyp in a sample may occur by obtaining a nucleic acid or polypeptide sample derived from intestinal tissue,  
20           and determining a gene expression profile from a gene expression product of at least one informative gene having decreased expression in an intestinal polyp relative to a control. Decreased expression of the informative gene is indicative of the presence of an intestinal polyp in the sample.

          As used herein, by “intestinal polyp” is meant abnormal cell growth in the  
25           intestines. Intestinal polyps can form in the upper intestines (for example, the small intestines) or the large intestines (also known as the colon). Intestinal polyps may be benign polyps (also referred to as non-neoplastic, hyperplastic, or inflammatory polyps), which do not appear to have the potential to develop into neoplastic polyps, or they may

be malignant polyps (also referred to as neoplastic polyps, adenomas, tubular adenomas, tubulovillous adenomas or villoglandular polyps). In addition, intestinal cancers can arise from previously benign polyps.

By “presence of an intestinal polyp” is meant that a sample, for example, a tissue sample contains an intestinal polyp or a cancerous intestinal polyp, or that the sample is at risk for, or has a likelihood of developing an intestinal polyp or a cancerous intestinal polyp.

By “absence of an intestinal polyp” is meant that a sample, for example, a tissue sample does not contain an intestinal polyp or a cancerous intestinal polyp, or that the sample has a decreased risk of, or has a decreased likelihood of developing an intestinal polyp or a cancerous intestinal polyp.

By “gene expression profile” is meant the level or amount of gene expression of particular genes, for example, informative genes, as assessed by methods described herein. The gene expression profile can comprise data for one or more informative genes and can be measured at a single time point or over a period of time. For example, the gene expression profile can be determined using a single informative gene, or it can be determined using two or more informative genes, three or more informative genes, five or more informative genes, ten or more informative genes, twenty-five or more informative genes, or fifty or more informative genes. A gene expression profile may include expression levels of genes that are not informative, as well as informative genes. Phenotype classification (e.g., the presence or absence of an intestinal polyp, or the identification of a compound that modulates intestinal polyp development) can be made by comparing the gene expression profile of the sample with respect to one or more informative genes with one or more gene expression profiles (e.g., in a database). Using the methods described herein, expression of numerous genes can be measured simultaneously. The assessment of numerous genes provides for a more accurate evaluation of the sample because there are more genes that can assist in classifying the sample. A gene expression profile may involve only those genes that are increased in



expression in a sample, only those genes that are decreased in expression in a sample, or a combination of genes that are increased and decreased in expression in a sample.

As used herein, “informative genes,” refers to a gene or genes whose expression correlates with a particular phenotype. Expression profiles obtained for informative genes can be used to determine, for example, the presence or absence of an intestinal polyp in a sample derived from intestinal tissue, or if a candidate compound increases or decreases gene expression in a sample. Samples can be classified according to their broad expression profile, or according to the expression levels of particular informative genes. The genes that are relevant for classification are referred to herein as “informative genes.” Not all informative genes for a particular class distinction must be assessed in order to classify a sample. Similarly, the set of informative genes that characterize one phenotypic effect may or may not be the same as the set of informative genes for a different phenotypic effect. For example, a subset of the informative genes that demonstrate a high correlation with a class distinction can be used in classifying the presence of an intestinal polyp. This subset can be, for example, one or more genes, two or more genes, three or more genes, five or more genes, ten or more genes, twenty-five or more genes, or fifty or more genes. The informative genes that characterize other classification categories such as, for example, a candidate compound that modulates intestinal polyp development, can be the same or different from the informative genes that characterize the presence or absence of an intestinal polyp. Typically the accuracy of the classification increases with the number of informative genes that are assessed.

Informative genes include, but are not limited to, apoptosis genes, cell cycle genes, tumor suppressor genes, cell adhesion genes, transcription related genes, inflammation genes, as well as the particular genes shown in Figures 1A-1U.

By an “apoptosis gene” is meant a gene or nucleic acid that encodes a polypeptide involved in the control of apoptosis. The apoptosis gene may be a gene involved in the promotion of apoptosis, or the apoptosis gene may be a gene involved in preventing apoptosis. Examples of apoptosis genes include, but are not limited to: TANK1 and Epiregulin.

By a “cell cycle gene” is meant a gene or nucleic acid that encodes a polypeptide involved in the control of the cell cycle. The cell cycle gene may be a gene involved in speeding up, slowing down, or arresting any phase of the cell cycle. Examples of cell cycle genes include, but are not limited to: CDK4/CDK6 inhibitor, RAN GTPase  
5 activating protein 1, and ubiquitin conjugating enzyme E2 variant 1.

By a “tumor suppressor gene” is meant is meant a gene or nucleic acid that encodes a polypeptide involved in decreasing or preventing tumor formation, development, or progression. Examples of tumor suppressor genes include, but are not limited to: prohibitin, non-receptor protein tyrosine kinase Ack, and PRG1.

10 By a “cell adhesion gene” is meant a gene or nucleic acid that encodes a polypeptide involved in the control of cell adhesion. The cell adhesion gene may be a gene involved increasing cell adhesion properties or decreasing cell adhesion properties. In addition, the cell adhesion gene may be involved in mediating cell-cell adhesion, or cell-extracellular matrix adhesion. Examples of cell adhesion genes include, but are not  
15 limited to: collagen type 1 $\alpha$ , E-cadherin, and Laminin  $\beta$ 3.

By a “transcription related gene” is meant a gene or nucleic acid that encodes a polypeptide involved in the control of transcription and/or translation. The transcription related gene may be a gene involved in, for example, transcription initiation, translation initiation, ribosome biogenesis, cytokinesis, chromatin remodeling, splicing, pre-rRNA  
20 processing, or telomerase formation. Examples of transcription related genes include, but are not limited to: Translation Initiation Factor EIF-2B- $\epsilon$  subunit, cleavage and polyadenylation specificity factor 73 kDa subunit, Nucleolin, cdc2/CDC28-like protein kinase 3 (Clk3), and hGAR1.

By an “inflammation gene” is meant a gene or nucleic acid that encodes a  
25 polypeptide involved in the control of a localized protective response elicited by injury or destruction of tissues, which serves to destroy, dilute or sequester both the injurious agent and the injured tissue. Inflammation is characterized in the acute form by the classical signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles,

capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocytic migration into the inflammatory focus. Inflammation genes may be found in a number of different cells, including cells of the immune system, for example, mast cells. Examples of inflammation genes include, but  
5 are not limited to chymase.

As used herein, “gene expression products” are proteins, polypeptides, or nucleic acid molecules (e.g., mRNA, tRNA, rRNA, cDNA, or cRNA) that result from transcription or translation of genes. The present invention can be used effectively to analyze proteins, polypeptides, or nucleic acid molecules that are the result of  
10 transcription or translation, particularly of informative genes identified herein. The nucleic acid molecule levels measured can be derived directly from the gene or, alternatively, from a corresponding regulatory gene or regulatory sequence element. All forms of gene expression products can be measured. For example, the nucleic acid molecule can be transcribed to obtain an RNA gene expression product. If desired, the  
15 transcript can be translated using, for example, standard *in vitro* translation methods to obtain a polypeptide gene expression product. Polypeptide gene expression products can be used in protein binding assays, for example, antibody assays, or in nucleic acid binding assays, standardly known in the art, in order to identify intestinal polyps or compounds involved in polyp development. Additionally, variants of genes and gene  
20 expression products including, for example, spliced variants and polymorphic alleles, can be measured. Similarly, gene expression can be measured by assessing the level of a polypeptide or protein or derivative thereof translated from mRNA. The sample to be assessed can be any sample that contains a gene expression product. Suitable sources of gene expression products, e.g., samples, can include intact cells, lysed cells, cellular  
25 material for determining gene expression, or material containing gene expression products. Examples of such samples are intestinal tissue, cells derived from intestinal tissue, nucleic acids or polypeptides derived from intestinal tissue, blood, plasma, lymph, urine, tissue, mucus, sputum, saliva, or other cell samples. Methods of obtaining such samples are known in the art.

By “increased expression” is meant the level of a gene expression product is made higher and/or the activity of the gene expression product is enhanced. Preferably, the increase is by at least 1.5-fold, more preferably the increase is at least 2-fold, 5-fold, or 10-fold, and most preferably, the increase is at least 20-fold, relative to a control. In the work described herein, a gene was considered to have increased expression in an intestinal polyp if it was expressed in at least 4 out of 8 polyp tissue samples (at least 2 of which were colonic and 2 of which were intestinal) and absent in all normal tissues.

By “decreased expression” is meant the level of a gene expression product is made lower and/or the activity of the gene expression product is lowered. Preferably, the decrease is at least 25%, more preferably, the decrease is at least 50%, 60%, 70%, 80%, or 90% and most preferably, the decrease is at least one-fold, relative to a control sample. In the work described herein, a gene was considered to have decreased expression if it was expressed in at least 4 out of 8 normal tissue samples (at least 2 of which were colonic and 2 of which were intestinal) and absent in all polyps.

Genes that are particularly relevant for classification, i.e., demonstrate a different expression profile in different classification categories, have been identified as a result of work described herein and are shown in Figures 1A-1U.

In one embodiment, the gene expression product is a protein or polypeptide. As used herein, by “polypeptide” is meant any chain of more than two amino acids, regardless of post-translational modification such as glycosylation or phosphorylation. Examples of polypeptides include, but are not limited to, proteins. In this embodiment the determination of the gene expression profile is made using techniques for protein detection and quantitation known in the art. For example, antibodies that specifically interact with the protein or polypeptide expression product of one or more informative genes can be obtained using methods that are routine in the art. The specific binding of such antibodies to protein or polypeptide gene expression products can be detected and measured by methods known in the art, for example, Western blot analysis or ELISA techniques.

In a preferred embodiment, the gene expression product is a nucleic acid, for example, DNA or mRNA, and the gene expression levels are obtained by contacting the sample with a suitable microarray on which probes specific for all or a subset of the informative genes have been immobilized, and determining the extent of hybridization  
5 of the nucleic acid in the sample to the probes on the microarray. Such microarrays are also within the scope of the invention. Examples of methods of making oligonucleotide microarrays are described, for example, in WO 95/11995. Other methods are readily known to the skilled artisan.

The gene expression value measured or assessed is the numeric value obtained  
10 from an apparatus that can measure gene expression levels. Gene expression levels refer to the amount of expression of the gene expression product, as described herein. The values are raw values from the apparatus, or values that are optionally re-scaled, filtered and/or normalized. Such data is obtained, for example, from a GeneChip® probe array or Microarray (Affymetrix, Inc.; U.S. Patent Nos. 5,631,734, 5,874,219,  
15 5,861,242, 5,858,659, 5,856,174, 5,843,655, 5,837,832, 5,834,758, 5,770,722, 5,770,456, 5,733,729, 5,556,752, all of which are incorporated herein by reference in their entirety), and the expression levels are calculated with software (e.g., Affymetrix GENECHIP software). For example, nucleic acids (e.g., mRNA or DNA) from a sample that has been subjected to particular stringency conditions hybridize to the  
20 probes on the chip. The nucleic acid to be analyzed (e.g., the target) is isolated, amplified and labeled with a detectable label, (e.g., <sup>32</sup>P or fluorescent label) prior to hybridization to the arrays. After hybridization, the arrays are inserted into a scanner that can detect patterns of hybridization. These patterns are detected by detecting the labeled target now attached to the microarray, e.g., if the target is fluorescently labeled,  
25 the hybridization data are collected as light emitted from the labeled groups. Since labeled targets hybridize, under appropriate stringency conditions known to one of skill in the art, specifically to complementary oligonucleotides contained in the microarray, and since the sequence and position of each oligonucleotide in the array are known, the identity of the target nucleic acid applied to the probe is determined.

Quantitation of gene profiles from the hybridization of a labeled nucleic acid microarray can be performed by scanning the microarray to measure the amount of hybridization at each position on the microarray with an Affymetrix scanner (Affymetrix, Santa Clara, CA ). For each stimulus a time series of nucleic acid levels (C={C1,C2,C3,...Cn}) and a corresponding time series of nucleic acid levels (M={M1,M2,M3,...Mn}) in control medium in the same experiment as the stimulus is obtained. Quantitative data is then analyzed. Hybridization analysis using microarray is only one method for obtaining gene expression values. Other methods for obtaining gene expression values known in the art or developed in the future can be used with the present invention. Once the gene expression values are determined, the sample can be classified.

Once the gene expression levels of the sample are obtained, the levels are compared or evaluated against a model or control sample(s), and then the sample is classified, for example, based on whether a particular informative gene in the sample exhibits increased or decreased expression. The evaluation of the sample determines whether or not the sample is assigned to a particular phenotypic class, for example, whether or not the sample contains a polyp or whether or not a candidate compounds modulates intestinal polyp development.

The correlation between gene expression and class distinction can be determined using a variety of methods. Methods for defining classes and classifying samples are described, for example, in U.S. Patent Application Serial No. 09/544,627, filed April 6, 2000 by Golub et al., the teachings of which are incorporated herein by reference in their entirety. The information provided by the present invention, alone or in conjunction with other test results, aids in sample classification.

In a preferred correlation method, the nucleic acid molecules were considered to be expressed in normal tissue and not in polyp tissue if the nucleic acid molecule was expressed in at least 4 out of 8 normal tissue samples (at least 2 of which were colonic and 2 of which were intestinal) and absent in all polyps. Nucleic acid molecules were considered to be expressed in polyp tissue and not in normal tissue if the nucleic acid

molecule was expressed in at least 4 out of 8 polyp tissue samples (at least 2 of which were colonic and 2 of which were intestinal) and absent in all normal tissues.

Accordingly, a gene can be considered to have increased expression in an intestinal polyp if it is expressed in at least 4 out of 8 polyp tissue samples (at least 2 of which  
5 were colonic and 2 of which were intestinal) and absent in all normal tissues.

Conversely, a gene can be considered to have decreased expression in an intestinal polyp if it is expressed in at least 4 out of 8 normal tissue samples (at least 2 of which were colonic and 2 of which were intestinal) and absent in all polyps. It should be recognized that one of skill in the art can apply more stringent or less stringent criteria  
10 in determining whether a gene expression product is increased or decreased.

The present invention also features methods for identifying compounds that modulate intestinal polyp development. Novel compounds identified as described herein are also the subject of the invention. Such methods involve contacting a sample, for example a cell, cell lysate, tissue, or tissue lysate, with a candidate compound, and  
15 detecting an increase in expression of at least one informative gene having decreased expression in an intestinal polyp. A candidate compound that increases expression of such an informative gene is a compound for use in modulating intestinal polyp development. Alternatively, a compound that modulates intestinal polyp development can be identified by contacting a sample, for example, a cell, cell lysate, tissue, or tissue  
20 lysate with a candidate compound, and detecting a decrease in expression of at least one informative gene having increased expression in an intestinal polyp. A candidate compound that decreases expression of such an informative gene is a compound for use in modulating intestinal polyp development. An increase or decrease in an informative gene may be identified using any of the methods described herein (or any analogous  
25 method known in the art). For example, oligonucleotide array systems described herein may be used to determine whether the addition of a test compound to a sample increases or decreases expression of an informative gene in that sample.

By “modulating intestinal polyp development” is meant increasing or decreasing the likelihood that an intestinal polyp will form or develop in a subject. The modulation

in intestinal polyp formation may be the result of contacting a sample (for example, a cell, tissue, cell or tissue lysate, nucleic acid, or polypeptide) with a candidate compound. Preferably, the sample is derived from intestinal tissue. It will be appreciated that the degree of modulation provided by a candidate compound in a given assay will vary, but that one skilled in the art can determine the statistically significant change or a therapeutically effective change in the degree or rate of polyp development.

By “intestinal polyp development” is meant the formation or progression of an intestinal polyp. Methods for monitoring intestinal polyp development are described herein.

By a “candidate compound” is meant a molecule, be it naturally-occurring or artificially derived, that is surveyed for its effects on the gene expression profile of an informative gene, employing methods described herein. Examples of candidate compounds include, but are not limited to peptides, polypeptides, synthetic organic molecules, naturally occurring organic molecules, nucleic acid molecules, and combinations thereof.

By “increasing gene expression” is meant raising the level of expression, and/or the activity, of one or more informative genes in a cell, tissue, cell lysate, or tissue lysate sample relative to a control sample. An increase in gene expression may occur, for example, when the sample is contacted with a candidate compound for use in modulating intestinal polyp development. The control sample may be a cell, tissue, cell lysate, or tissue lysate that was not contacted with the candidate compound or that was contacted with candidate compound vehicle only. Preferably, the increase is at least 1.5-fold, more preferably the increase is at least 2-fold, 5-fold, or 10-fold, and most preferably, the increase is at least 20-fold, relative to a control sample.

By “decreasing gene expression” is meant lowering the level or expression of, and/or the activity of, one or more informative genes in a cell, tissue, cell lysate, or tissue lysate sample relative to a control sample. A decrease in gene expression may occur, for example, when the sample is contacted with a candidate compound for use in modulating intestinal polyp development. The control sample may be a cell, tissue, cell



lysate, or tissue lysate that was not contacted with the candidate compound or that was contacted with candidate compound vehicle only. Preferably, the decrease in gene expression of an informative gene is at least 25%, more preferably, the decrease is at least 50%, 60%, 70%, 80%, or 90% and most preferably, the decrease is at least one-  
5 fold, relative to a control sample.

The expression level of an informative gene may be modulated by modulating transcription, translation, or mRNA or protein turnover, or the activity of the gene expression product, and such modulation may be detected using known methods for measuring mRNA and protein levels and activities, e.g., oligonucleotide microarray  
10 hybridization, RT-PCR, and ELISA and nucleic acid and protein binding assays.

A compound that increases the expression level of a gene that is decreased in an intestinal polyp can be useful for treating intestinal polyps or intestinal cancer. In addition, a compound that decreases the expression level of a gene that is increased in an intestinal polyp can also be useful for treating intestinal polyps or intestinal cancer.

15 While the above described candidate compound screening methods are designed primarily to identify candidate compounds that may be used to decrease intestinal polyp development, identification of candidate compounds that increase intestinal polyp development is also a feature of the present invention. Such candidate compound identification methods involve contacting a sample, for example, a cell, cell lysate,  
20 tissue, or tissue lysate with a candidate compound, and detecting an increase in expression of at least one informative gene having increased expression in an intestinal polyp. A candidate compound that increases expression of such an informative gene is a compound for use in modulating intestinal polyp development.

Alternatively, a compound that modulates intestinal polyp development can be  
25 identified by contacting a sample, for example, a cell, cell lysate, tissue, or tissue lysate with a candidate compound, and detecting a decrease in expression of at least one informative gene having decreased expression in an intestinal polyp. A candidate compound that decreases expression of such an informative gene is a compound for use in modulating intestinal polyp development. These candidate compound identification

methods may be used for identifying compounds that increase intestinal polyp development or intestinal cancer, or the risk of intestinal polyp development or intestinal cancer. Such compounds may be identified as compounds to which exposure should be minimized in order to decreased one's likelihood of developing intestinal polyps or intestinal cancer.

In general, novel drugs for modulation of polyp development can be identified from large libraries of natural products or synthetic (or semi-synthetic) extracts or chemical libraries according to methods known in the art. Those skilled in the field of drug discovery and development will understand that the precise source of test extracts or compounds is not critical to the screening procedure(s) of the invention. Accordingly, virtually any number of chemical extracts or compounds can be screened using the exemplary methods described herein. Examples of such extracts or compounds include, but are not limited to, plant-, fungal-, prokaryotic- or animal-based extracts, fermentation broths, and synthetic compounds, as well as modification of existing compounds. Numerous methods are also available for generating random or directed synthesis (e.g., semi-synthesis or total synthesis) of any number of chemical compounds, including, but not limited to, saccharide-, lipid-, peptide-, and nucleic acid-based compounds. Synthetic compound libraries are commercially available, e.g., Chembridge (San Diego, CA). Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant, and animal extracts are commercially available from a number of sources, including Biotics (Sussex, UK), Xenova (Slough, UK), Harbor Branch Oceanographics Institute (Ft. Pierce, FL), and PharmaMar, U.S.A. (Cambridge, MA). In addition, natural and synthetically produced libraries are generated, if desired, according to methods known in the art, e.g., by standard extraction and fractionation methods. Furthermore, if desired, any library or compound is readily modified using standard chemical, physical, or biochemical methods.

In addition, those skilled in the art of drug discovery and development readily understand that methods for dereplication (e.g., taxonomic dereplication, biological dereplication, and chemical dereplication, or any combination thereof) or the

elimination of replicates or repeats of materials already known for their polyp development-modulatory activities should be employed whenever possible.

When a crude extract is found to modulate (i.e., stimulate (increase) or inhibit (decrease)) intestinal polyp development, further fractionation of the positive lead  
5 extract is desirable to isolate chemical constituents responsible for the observed effect. Thus, the goal of the extraction, fractionation, and purification process is the careful characterization and identification of a chemical entity within the crude extract having an activity that increases or decreases. The same assays described herein for the detection of activities in mixtures of compounds can be used to purify the active  
10 component and to test derivatives thereof. Methods of fractionation and purification of such heterogenous extracts are known in the art. If desired, compounds shown to be useful agents for treatment are chemically modified according to methods known in the art. Compounds identified as being of therapeutic value may be subsequently analyzed using animal models for diseases, for example, the Min mouse model described herein,  
15 in which it is desirable to increase or decrease intestinal polyp development.

Informative genes identified as described herein can also be targeted in methods of modulating intestinal polyp formation or development. For example, expression of at least one informative gene shown to be expressed in intestinal polyp tissue or expressed in increased levels, but not in normal intestinal tissue can be down-regulated in a  
20 method of inhibiting polyp formation or development. Alternatively, expression of at least one informative gene shown not to be expressed in intestinal polyp samples, or which are expressed in reduced levels relative to normal intestinal samples can be upregulated in a method of inhibiting intestinal polyp formation or development. Compounds identified by methods described herein, for example, can be utilized in  
25 methods of treatment of intestinal polyps.

The present invention also features arrays, for example, microarrays that have a plurality of oligonucleotide probes involved in intestinal polyp development immobilized thereon. The oligonucleotide probe may be specific for one or more informative genes, selected from apoptosis genes, cell cycle genes, tumor suppressor

2825.2018-001

genes, cell adhesion genes, transcription related genes, and inflammation genes and/or from those in Figures 1A-1U. Methods for making oligonucleotide microarrays are well known in the art, and are described, for example, in WO 95/11995, the entire teachings of which are hereby incorporated by reference.

5           The present invention also provides information regarding the genes that are important in intestinal polyp development, thereby providing additional targets for diagnosis and therapy. It is clear that the present invention can be used to generate databases comprising informative genes that will have many applications in medicine, research and industry; such databases are also within the scope of the invention.

10           The invention will be further described with reference to the following non-limiting examples. The teachings of all the patents, patent applications and all other publications and websites cited herein are incorporated by reference in their entirety.

## EXEMPLIFICATION

### Methods

15           A Min (Many intestinal neoplasias) mouse, which contains a mutant adenomatous polyposis coli (APC) gene and is a model for familial adenomous polyposis, was used in the procedures described herein to identify genes involved in intestinal polyp development. One Min mouse was sacrificed, and 4 polyps from the upper intestine (upper intestinal polyps) and 4 polyps from the colon (colonic polyps)  
20           were isolated. For each upper intestinal polyp, a similarly sized piece of tissue determined to be normal by microscopic evaluation was isolated from upper intestinal tissue. For each colonic polyp, a similarly sized piece of tissue determined to be normal by microscopic evaluation was isolated from colon tissue.

          DNA was amplified from each of the samples utilizing an amplification  
25           procedure as described in U.S. Provisional patent application Serial No. 60/193,708 by de Graaf et al., filed March 31, 2000 and U.S.S.N. 09/822,789, by de Graaf et al., filed March 30, 2001, the entire teachings of which are incorporated by reference. Amplified

2825.2018-001

DNA was then subjected to hybridization to nucleic acid arrays obtained from Affymetrix, Inc., which contained probes for approximately 13,000 mouse genes and ESTs (GeneChip® MU11K Set, Affymetrix, Inc., Santa Clara, CA). Results obtained from these arrays provide a quantitative readout for expression of nucleic acid

5 molecules within the hybridized sample.

The gene expression data obtained as described above was assessed to identify specific nucleic acid molecules (e.g., ESTs, genes) whose expression differed between polyp samples and normal tissue. Nucleic acid molecules were considered to be expressed in normal tissue and not in polyp tissue if the nucleic acid molecule was

10 expressed in at least 4 out of 8 normal tissue samples (at least 2 of which were colonic and 2 of which were upper intestinal) and was absent in all polyps. Nucleic acid molecules were considered to be expressed in polyp tissue and not in normal tissue if the nucleic acid molecule was expressed in at least 4 out of 8 polyp tissue samples (at least 2 of which were colonic and 2 of which were upper intestinal) and was absent in

15 all normal tissues.

## Results

A listing of the nucleic acid molecules which were differentially expressed in intestinal polyp and normal intestinal tissue is shown in the table shown in Figures 1A-1U. Figure 1V provides a key depicting how Figures 1A-1U are assembled to produce a

20 complete table. The first column of the table shows the nucleic acid molecule name, and the second column shows the Affymetrix annotation. Columns 3-6 show expression data for the colonic polyp samples (L1-L4), and Columns 7-10 show expression data for the normal colon samples (LC1-LC4). Columns 11-14 show expression data for the intestinal polyp samples (U1-U4), and Columns 15-18 show

25 expression data for the normal intestinal samples (UC1-UC4). Columns 19-20, 21-22, 23-24, and 25-26 show the average expression value and standard deviation, respectively, for the groups of colonic expression, small intestine expression, polyp expression, and normal tissue expression, respectively. Column 27 shows a short

description of the function of the nucleic acid molecule shown in Column 1 (if available).

### **Genes with Decreased Expression in Intestinal Polyps**

The screen identified 7 genes that were determined to be “censored” by giving  
5 exhibiting decreased expression in polyp samples. In some instances, it was difficult to  
determine whether a sample provided this negative readout because the amount of the  
nucleic acid present in the sample was too small to detect (was not sufficiently  
amplified) or because the gene product was not expressed; such data is referred to herein  
as “censored”. Genes identified as censored include insulin-like growth factor binding  
10 protein 1, which is a regulator of apoptosis; caspase 7, which encodes a protein that is  
stored in the mitochondrial intermembrane space and released into the cytosol after  
appropriate apoptotic stimuli, promoting apoptosis and interacting with calpain; and  
opioid growth factor receptor, which regulates cellular renewal and wound healing, and  
also inhibits pancreatic and squamous cell carcinomas. In addition, 3 ESTs and one  
15 nucleic acid sequence with a previously unknown function were also determined to be  
genes that were censored in polyps.

### **Genes with Increased Expression in Intestinal Polyps**

A number of nucleic acid molecules were expressed in intestinal polyp samples  
but not in normal tissue. These nucleic acid molecules can be categorized into families  
20 based on function. For example, a number of genes involved in cell cycle or tumor  
suppression were identified, including CDK4/CDK6 inhibitor, which is a p19 regulator  
of passage through the G1 checkpoint of the cell cycle; RAN GTPase activating protein  
1, which controls progression through the cell cycle by regulating the transport of  
proteins and nucleic acids across the nuclear membrane; prohibitin, which is a potential  
25 tumor suppressor, regulating E2F1 function; non-receptor protein tyrosine kinase Ack,  
which inhibits Ras-induced malignant phenotypes in fibroblasts; PRG1, which is an  
early-response gene transcriptionally induced by p53; and ubiquitin conjugating enzyme

E2 variant 1, which is involved in the control of differentiation and the entry of a larger proportion of cells in the division cycle and an accumulation in G2-M of the cell cycle.

In addition, two genes involved in apoptosis were identified as exhibiting increased expression in intestinal polyps, TANK1, a tumor necrosis receptor-associated factor- (TRAF) interacting protein, which is a mediator of NF $\kappa$ B activation after induction by TRAF2, and an apoptosis inhibitor; and Epiregulin, an epidermal growth factor family member. Downregulation of the epidermal growth factor pathway leads to apoptosis.

Another family of genes identified as being upregulated in intestinal polyps is a group of genes involved in cell adhesion. For example, collagen type 1 $\alpha$ , which directly interacts with laminin; E-cadherin, which is in direct contact with APC, a negative regulator of polyp formation; and Laminin  $\beta$ 3, an upstream regulator of E-cadherin were identified as having increased expression in intestinal polyps.

In addition, a number of genes involved in transcription were identified as having increased expression in intestinal polyps, including Translation Initiation Factor EIF-2B- $\epsilon$  subunit; cleavage and polyadenylation specificity factor 73 kDa subunit; Nucleolin, which is involved in ribosome biogenesis, cytokinesis, nucleogenesis, cell proliferation and growth, and chromatin remodeling; cdc2/CDC28-like protein kinase 3 (Clk3), which includes one catalytically active and one inactive isoform, interacting with and inducing the nuclear redistribution of SR proteins; and hGAR1, which is a component of H/ACA snoRNPs and telomerase.

Other genes identified as having increased expression in intestinal polyps, compared to normal intestinal tissue include myosin IC, which is an unconventional crypt cell marker; carboxypeptidase E, which is a metallo carboxypeptidase family member that functions as a regulated secretory pathway sorting receptor, and is involved in the trimming of paired basic residues at the C terminus of prohormone-derived peptides. Other genes identified in the screen as being upregulated in intestinal polyps include cytochrome p450, which is involved in the metabolism of aromatic substances;

thymidine kinase 1, which is involved in the pyrimidine salvage pathway, and is also a soluble, putative up-regulated c-Myc target gene; and Guanine-Binding Protein  $\beta$ -subunit, which is involved in GDP to GTP exchange.

In addition, a gene with similarities to the Glycogen phosphorylase gene, as well  
5 as 23 ESTs or sequences with previously unknown function were also identified in the above-described screen.

While this invention has been particularly shown and described with references  
to preferred embodiments thereof, it will be understood by those skilled in the art that  
various changes in form and details may be made therein without departing from the  
10 scope of the invention encompassed by the appended claims.

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194